2023-05-05 16:21:29 ET
- Entera Bio press release ( NASDAQ: ENTX ): Q1 GAAP EPS of -$0.08 beats by $0.04 .
- As of March 31, 2023, Entera had cash and cash equivalents of $10.7 million.
- Entera expects that its existing cash resources are sufficient to meet its projected operating requirements into the third quarter of 2024, which includes the capital required to fund our ongoing operations, including R&D and the completion of the Phase 1 PK study related to the new formulation of EB612.
- Shares +3.39% .
For further details see:
Entera Bio GAAP EPS of -$0.08 beats by $0.04